US Neurology Editorial Board member, Aksel Siva (Istanbul University, Cerrahpaşa School of Medicine, Istanbul, Turkey), discusses latest initiatives in the diagnosis of neuro-Behçet disease, a rare and relatively unknown neurological disorder, as well as promising investigational therapies.
- How can MRI imaging parameters be used in the differential diagnosis of neuro-Behçet disease and other central nervous system inflammatory disorders? (0:04)
- What are the limitations of current treatment options for neuro-Behçet disease? (3:17)
- What investigational therapies appear most promising? (5:39)
View Part 1 of this expert interview here.
Speaker disclosures: Aksel Siva has nothing to disclose in relation to this video interview.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Neuromuscular Diseases
Renato Mantegazza, EAN 2021: Challenges in the Treatment of Myasthenia Gravis
touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy) to discuss the challenges that arise in treating patients with myasthenia gravis. The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was presented at the 7th […]
Jeffrey Guptill, AAN 2021: Vivacity-MG Study Results
We were delighted to meet with Jeffery Guptill (Duke University Medical Center, Durham, NC, USA) to discuss the Vivacity-MG study results (NCT03772587), investigating nipocalimab as a treatment option for Myasthenia Gravis. The abstract entitled: ‘Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab […]
Tahseen Mozaffar: PROPEL Study Results
TouchNEUROLOGY caught up with Tahseen Mozaffar (University California, Irvine, CA, USA) to discuss the results from the PROPEL study (NCT03729362) investigating the use of AT-GAA for the treatment of late-onset Pompe disease. Questions: Could you tell us a little about late onset Pompe disease and the unmet needs in its treatment? (0:15) What is AT-GAA […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!